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Abstract
Infection of hepatitis B virus (HBV) causes acute and chronic hepatitis and is closely associated with the development of
cirrhosis and hepatocellular carcinoma (HCC). Previously, we demonstrated that the G1613A mutation in the HBV negative
regulatory element (NRE) is a hotspot mutation in HCC patients. In this study, we further investigated the functional
consequences of this mutation in the context of the full length HBV genome and its replication. We showed that the
G1613A mutation significantly suppresses the secretion of e antigen (HBeAg) and enhances the synthesis of viral DNA,
which is in consistence to our clinical result that the G1613A mutation associates with high viral load in chronic HBV carriers.
To further investigate the molecular mechanism of the mutation, we performed the electrophoretic mobility shift assay with
the recombinant RFX1 protein, a trans-activator that was shown to interact with the NRE of HBV. Intriguingly, RFX1 binds to
the G1613A mutant with higher affinity than the wild-type sequence, indicating that the mutation possesses the trans-
activating effect to the core promoter via NRE. The trans-activating effect was further validated by the enhancement of the
core promoter activity after overexpression of RFX1 in liver cell line. In summary, our results suggest the functional
consequences of the hotspot G1613A mutation found in HBV. We also provide a possible molecular mechanism of this
hotspot mutation to the increased viral load of HBV carriers, which increases the risk to HCC.
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Introduction
Hepatitis B virus (HBV) infection is a considerable burden to
health in the Asian-Pacific region. It causes acute and chronic
hepatitis which is closely associated with the development of
cirrhosis and hepatocellular carcinoma (HCC). Approximately
60–80% of world’s HCC is related to HBV. It is estimated that
chronic HBV carriers would have 100 times higher risk developing
HBV-related HCC compared to uninfected individuals [1]. HBV
is classified into 8 genotypes (A–H) with distinct geographical
distribution and can be further divided into a total of 24
subgenotypes [2,3]. Genotypes B and C are predominant in
South-east Asia. In East (Korea and Japan) and northern China,
HBV subgenotype Ce is more prevalent whereas subgenotype Cs
is usually found in Southeast Asia, including Vietnam, Thailand,
Malaysia, and southern China [4].
HBV DNA is a relaxed circular, partially double-stranded
molecule of 3.2 kb. It contains four partially overlapping open-
reading frames (ORFs) which codes for seven proteins. The PreC/
C ORF encodes for the precore and core proteins. The precore
protein is posttranslationally modified to form the secretory e
antigen (HBeAg) whereas the core protein is the structural protein
which composes the capsid of the virus. The polymerase (P) ORF
encodes for the viral polymerase-reverse transcriptase. The preS/S
ORF encodes for various surface proteins whereas the X ORF
encodes for a transcriptional transactivator X protein (HBx). One
of the characteristics of HBV genome is the partially overlapping
of the genes. In order to reduce the disruption of the genes in the
HBV genome, 1.36 HBV genomes was often used for in-vitro
studies [5]. The organization of the genome is depicted in
Figure 1A.
HBV is hepatotrophic due to its specific interaction of various
liver-enriched transcription factors such as HNF-4, HNF-3 and C/
EBP [6]. The HBV core promoter is essential to the viral
replication, as it regulates the transcription of the pregenomic
RNA (pgRNA) and precore (preC) mRNA. The pgRNA is then
translated to core protein and the viral polymerase, as well as
being a template for viral replication, whereas the preC mRNA
codes for a precursor protein of HBeAg which is a serological
marker used for HBV infection diagnosis [7].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21856The core promoter is composed of two regions, the basal core
promoter (BCP) and the upper regulatory region (URR) [8]
(Figure 1B). The BCP (nt. 1742–1849) region contains cis-acting
element which initiates the transcription of pgRNA and preC
mRNA [9]. Although both transcripts are driven by the same
promoter, their transcriptions are differentially regulated [10]. In
BCP region, a double mutation, A1762T/G1764A, is commonly
found to associate with HBV genotype C [11], which affects the
viral replications. The URR consists of the negative regulatory
element (NRE, nt. 1613–1636) and the core upstream regulatory
sequence (CURS, nt. 1637–1742) (Figure 1B). Both elements
overlap the enhancer II (ENII, nt. 1627–1774) that recruits liver-
enriched transcription factors for its activity. The CURS can
activate the BCP in well-differentiated hepatoma cells through cis-
acting elements immediately upstream of BCP in an orientation-
and position-dependent manner [12,13]. Nevertheless, the stim-
ulatory effect of ENII and CURS can be repressed by the effect of
upstream NRE [12]. The NRE is composed of three subregions:
NREa, NREb and NREc [14]. The RFX1, a transactivating
protein, was demonstrated to bind the NREc region but not
in randomly introduced NREc mutants [14]. Moreover, the
sequence of NREc shares 85% similarity with the RFX1
consensus binding sequences, suggesting that RFX1 is one of the
transactivators that regulate the viral replication of HBV
[15,16,17].
Recently, several factors and cis-acting elements were shown to
involve in the posttranscriptional control of the HBV gene
expression. Posttranscriptional regulatory elements (PRE) have
been found at the 39 end of all HBV transcripts as they terminate
at a common polyadenylation site [18]. The PRE was predicted to
contain multiple functional conserved elements at nucleotide
positions 1151–1410, 1411–1433 and 1510–1620. Although the
exact role of the PRE has yet to be elucidated [15,16], PRE have
been shown to be required for efficient HBV surface protein
expression by facilitating the cytoplasmic localization of surface
protein mRNA [19,20], and contribute to the HBV RNA stability
through the interaction with human La protein [21,22,23,24,25].
In addition, although splicing of HBV RNA is not required to
produce viral proteins, spliced variants of HBV RNAs have been
detected in sera and in liver samples in vivo and in vitro [20]. A
splicing regulatory element on PRE is found in stimulating the
splicing as a result of RNA-protein and protein-protein interaction
[26]. However, it remains unclear if splicing variants have any
important role in the life cycle of HBV.
In our previous study [27], the G1613A mutation was identified
as a hotspot in HCC patients. Coincidently, the mutation is
situated on the NREc on core promoter, as well as the conserved
region within PRE on HBV RNAs. In this study, we set out to
elucidate the functional consequences of the G1613A mutation on
the synthesis of HBV serological markers, HBeAg and HBV
surface antigen (HBsAg), as well as the production of viral DNA
and RNA. We showed that the G1613A mutation is associated to
high viral load in HBV carriers with statistically significance.
Moreover, this mutation enhanced the HBV viral DNA
production and suppressed the secretion of HBeAg. Intriguingly,
the hotspot mutation locates in the RFX1 consensus binding
sequence of the NREc region. We further showed that RFX1
transactivates the core promoter activity by interacting to the
Figure 1. Schematic diagrams of HBV genome and core promoter. (A) The genome organization of 1.36HBV genome used in this study (nt.
980–2000). The numbering of the nucleotide start at the unique EcoRI site as ‘1’ indicated in the middle of the genome. The two ends contains
repeated parts from nt. 980–1821 and nt. 1825–2000 (dark grey colour) including the polyadenylation signal located downstream of the core
promoter. The whole genome was cloned into pUC18 vector. The genes in the genome are partially overlapping. ORF: open reading frame; pro:
promoter; X: region coding for X protein; PreC/C: precore/core region coding the precore and core protein; PreS/S: region coding for large, middle
and small surface proteins; P: region coding for viral polymerase. (B) The major elements in HBV core promoter. The core promoter overlaps with 59
end of X ORF and enhancer II (ENII). The activity of the basal core promoter (BCP) is regulated by the upper regulatory region (URR), which is further
divided into negative regulatory element (NRE) and the core upstream regulatory sequence (CURS).
doi:10.1371/journal.pone.0021856.g001
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demonstrated the functional consequences of the G1613A
mutation, and suggested a possible molecular link between the
mutation and the resulted phenotype of the virus.
Materials and Methods
Patients in the study of viral load and G1613A mutation
Residual serum samples from a cohort of chronic hepatitis B
patients undergoing a surveillance program for hepatocellular
carcinoma recruited from the Hepatology Clinic, Prince of Wales
Hospital from October 1997 to November 2000 was studied [28].
Based on sequencing of the HBV S gene, 255 chronic carriers
were confirmed to have subgenotype Cs HBV infection. The
configuration of nt. 1613 was determined in the available residual
serum samples of these patients by direct DNA sequencing.
Alignment of HBV NRE sequences of genotype C
The HBV sequences were obtained from National Center for
Biotechnology Information (GenBank) database (http://www.
ncbi.nlm.nih.gov/). A total of 805 HBV sequences of genotype
C were aligned within the nt. 1604–1636. The counts of each base
within nt. 1611–1619 were calculated.
Construction of promoter clones from patient isolates
Constructs of HBV core promoters (nt. 1575–1813) were
derived from HBV isolates extracted from patients’ serum. The
original configuration of nt. 1613 on the core promoter isolated
from the carrier was ‘G’, and it was mutated to ‘A’ by site-directed
mutagenesis. These constructs are belonged to HBV subgenotype
Cs. The HBV preS1 promoter, of nucleotide 2706–2887, was used
as control. The purified PCR products were cleaved by XhoI and
HindIII (Amersham Biosciences). After purification, the digested
product were ligated into pGL3-basic vector (Promega) and finally
cloned and purified by Midi Kit (Qiagen) according to
manufacturer’s instruction. The sequences of all the constructs
were confirmed by DNA sequencing.
Construction of 1.36HBV genomes of G1613A mutants
with/without the BCP mutation
HBV DNA of subgenotype Cs extracted from a chronic carrier
was used as template. The 1.36HBV constructs was designed to
follow the organization of the 1.56 HBV clone (genotype A)
provided from VIDRL, only with a shorter genome length. It
starts from the X promoter (nt. 980) and extended more than one
genome length to include two copies of X ORF. It ends 80 base
pairs downstream of the poly(A) signal to include the cis-regulatory
elements for effective replication (nt. 2000). The G1613A mutation
and the BCP mutation were introduced into both 59 and 39 copy
of the core promoter in the genome by site directed mutagenesis.
Transfection of 1.36HBV genomes
Human hepatoma cells HuH7 purchased from Japanese
Collection of Research Bioresources Cellbank (JCRB) (cell
number: JCRB0403) were seeded on 60-mm dishes in 5 ml of
complete DMEM to obtain approximately 60% confluent on the
day of transfection. The 1.36 HBV genome, together with
pSEAP-Control plasmid (secreted human placental alkaline
phosphatase as transfection efficiency control) was transfected
using FuGENE 6 (Roche Applied Science). Growth media were
changed 2 days after transfection. The transfection efficiency was
normalized by the secreted alkaline phosphatase (SEAP) activity in
the culture media. The SEAP Reporter Gene Assay (Roche
Applied Science) was performed according to the manufacturer’s
instruction.
Measurement of HBeAg and HBsAg levels
Fifty microliters of supernatant and cell lysate was collected for
extracellular and intracellular HBeAg and HBsAg detection
respectively by Microparticle Enzyme Immunoassay (AUTOBIO
Diagnostics Co. Ltd) according to manufacturer’s instruction. All
readings exceeded the cut off value were interpreted as positive.
They were normalized to the result of SEAP reporter assay as
transfection efficiency control.
HBV DNA extraction
Intracellular HBV DNA was prepared by adding 800 mll y s i s
buffer (10 mM Tris pH 7.5, 1 mM EDTA, 50 mM NaCl and 0.5%
NonidetP-40) to the cellsat 4uC for 15 min. Cellslysates were spun at
8,0006g for 5 min to remove the nuclei. Transfected plasmid DNA
was eliminated from cell lysate by treatment with DNaseI (20 U) and
MgCl2, and incubated at 37uC for 2 hr. Then followed by adding 56
stop buffer [2.5% (w/v) sodium dodecyl sulphate (SDS), 100 mM
Tris pH 7.5 and 125 mM EDTA] for inactivation and proteinase K
(Invitrogen) to a final concentration of 0.5 mg/ml. The samples were
incubated at 37uC overnight for complete digestion of the core
particles and release of HBV DNA. Extracellular HBV DNA was
collected in supernatant at 5-day posttransfection. The core particles
in the supernatant were precipitated by 26% polyethylene glycol
buffer (Sigma)at 4uCovernight, and spun at 16, 0006gfor20 minat
4uC. The pellet was then resuspend in 200 ml virus buffer (10 mM
Tris pH 7.5 and 5.5 mM MgCl2), then lysed by 56stop buffer and
treated with proteinaseK as the intracellular HBV DNA preparation.
Afterwards, the intracellular and extracellular HBV DNA was
extracted using Qiamp DNA mini kit (Qiagen) according to
manufacturer’s instructions. DNA was finally eluted into 50 mlo f
nuclease-free water.
Real-time quantitative PCR of HBV DNA
Two microliters of 50-fold diluted DNA was used in 10 ml real-
time PCR reaction mixture with 16 SYBR-green power master
mix and 7500 Fast Real-Time PCR System (Applied Biosystems).
Intracellular and extracellular HBV DNA was detected by primers
according to Mendy et al. [16]. Each test run included positive and
negative controls. The reaction condition was modified to 95uC
for 10 min followed by 40 cycles of 95uC for 15 s and 61.5uC for
1 min. The level of HBV DNA was expressed in relative to the
corresponding wild-type G1613 construct.
Southern blot and HBV DNA hybridization
The amount of HBV DNA extracted from both intracellular
and extracellular cores from each plate of transfected cells was
normalized using the SEAP activity as an internal control as
reported previously [29]. After electrophoresis in a 1.5% agarose
gel, HBV core DNA was blotted onto a nylon membrane. Twenty-
five nanograms of full-length HBV DNA (subgenotype Cs) was
labeled by random primer with [
32P]dCTP and used as the probe
for hybridization. The blots were hybridized at 42uC overnight
and followed by washing. The membranes were exposed to
phosphorimager plates and scanned by phosphorimager reader.
Densitometry of each lane was performed for semi-quantification
of the intensity of signals.
Northern blot analysis
Total cellular RNA was extracted from transfected cells with
Trizol reagent as described above. Following the standard method
G1613A Mutation on HBV
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gels, transferred onto nylon membrane and fixed by UV
irradiation. Hybridization and exposure were similar to that
described for Southern blotting. To normalize to the transfection
efficiency, the amount of RNA was calibrated according to the
relative SEAP activities.
Construction of pCMV-TNT-RFX1 clone
The cDNA clone of Homo sapiens regulatory factor X1 (RFX1)
was purchased from OriGene Technologies, Inc. (catalogue
no. RC207872). The plasmid has been derived from single clone
E. coli cultures and purified as 10 mg transfection-ready dried
plasmid DNA. The plasmid contained the full-length RFX1 ORF
with a myc-tag at the C-terminal cloned into the pCMV6 Entry
vector (pCMV-RFX1). The sequence of this clone matched the
reference sequence published in the National Center for
Biotechnology Information with accession no. NM_002918.3.
The full-length ORF of RFX1 in pCMV-RFX1 plasmid was
subcloned into pCMVTNT
TM Vector (Promega), which is
designed for the convenient expression of cloned genes using
in vitro expression systems. The PCR reaction included 0.2 mM
each of forward and reverse primers, 1 ml of 1000-fold diluted
pCMV-RFX1 and 25 mlo f2 6 PicoMaxx mastermix in a total
volume of 50 ml. The PCR was performed with a 3 min initial
denaturation at 94uC, followed by 32 cycles of amplification (94uC
for 36 s, 58uC for 30 s and 72uC for 3 min) and a final extension
at 72uC for 10 min. The PCR products were examined in 1%
TAE agarose gel and purified by gel extraction kit (Qiagen),
followed by XhoI and MluI digestion in 16NEB buffer 3 at 37uC
for 16 hr. After that, the digested fragment was ligated to XhoI/
MluI digested pCMV-TNT empty vector and subsequently
transformed to E. coli and purified. The DNA sequences of the
RFX1 construct (pCMV-TNT-RFX1) was confirmed by DNA
sequencing.
In vitro transcription/translation of RFX1 protein
The RFX1 gene was in vitro transcribed and translated using
TNTH Quick Coupled Transcription/Translation Systems (Pro-
mega) according to manufacturer’s instruction. In brief, the
reaction contained 40 ml of Quick TNT master mix, 2 mlo f
radioactive
35S-methionine (1000 Ci/mmol) (Perkin Elmer) or
20 mM of methionine, and 1–5 mg of DNA in 50 ml of reaction.
The mixture was incubated at 30uC for 90 min and the labeled
translation products were analyzed by 10% SDS-PAGE. Then,
the gel was blotted on 3 mm Whatman paper and dried at 75uC
for 1 hr, followed by signal detection by autoradiography or
phosphorimager.
Electrophoretic mobility shift assay (EMSA)
To find out endogenous nuclear proteins in HuH7 that bound
to the NRE region of the core promoter. G1613 (wild-type) (sense
59-GCACGTCGCATGGAGACCACCGTGAACGCGC-39; an-
tisense 59-GGCGTTCACGGTGGTCTCCATGCGACGTGC-
39) and A1613 (mutant) (sense 59- GCACGTCGCATGGAAAC-
CACCGTGAACGCC-39; antisense 59- GGCGTTCACGGTG-
GTTTCCATGCGACGTGC-39) annealed NRE probes were
used. The sequences of the probes are the same except for the nt.
1613 (underlined). Nuclear and cytoplasmic extracts of HuH7 cells
were isolated by NE-PER Nuclear and Cytoplasmic Extraction
Reagents (PIERCE Biotechnology) according to manufacturer’s
instruction. The protein was aliquoted and kept at 280uC until
use. Annealed G1613 (wild-type) and A1613 (mutant) NRE probes
and annealed non-specific oligos (sense 59- GGAATTACGTGG-
Table 1. The prevalence of G1613A mutation in HBV carriers and HCC patients.
HBV Genotype/subgenotype Cases Number of cases Nucleotide at 1613 ##P value
G(%) A(%)
#R( % )
B (N=87) Carriers 50 39 (78) 11(22.0) 0 (0) .175
HCC 37 24 (64.9) 13 (35.1) 0 (0)
Cs (N=86) Carriers 39 33 (84.6) 4 (10.3) 2 (5.1) * .003
HCC 47 29 (61.7) 17 (36.2) 1 (2.1)
Ce (N=26) Carriers 10 9 (90.0) 1 (10.0) 0 (0) .179
HCC 16 9 (56.3) 6 (37.5) 1 (6.3)
*The G1613A mutation was found significantly higher prevalent in HCC patients in subgenotype Cs.
#R represents purines, A or G.
##P value was determined using chi’s square analysis in SPSS software. A P-value of .05 or less is regarded as statistically significant.
doi:10.1371/journal.pone.0021856.t001
Table 2. Analysis of 803 NRE sequences of HBV genotype C.
Position Nucleotide on HBV NRE region Count %
1611 G 803 100.0
1612 A 795 99.0
C8 1 . 0
a1613 G 583 72.6
A 209 26.0
R1 1 1 . 4
1614 A 798 99.4
G5 0 . 6
1615 C 803 100.0
1616 C 803 100.0
1617 A 799 99.5
T2 0 . 2
C2 0 . 2
1618 C 803 100.0
1619 C 803 100.0
aThe nucleotide 1613 is the only hot spot mutation within nt. 1611–1619. The
HBV NRE sequences were obtained from National Center for Biotechnology
Information (GenBank) database (http://www.ncbi.nlm.nih.gov/).
doi:10.1371/journal.pone.0021856.t002
G1613A Mutation on HBV
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21856Table 3. The relationship between the prevalence of G1613A mutation and viral load in HBV chronic carriers of subgenotype Cs.
Cases Viral load Nucleotide at 1613 #P value
##Harzard Ratio
(N=255) (log copies/ml) G (%) A (%) (95% CI)
Male (N=167) ,6 62 (78.5) 17 (21.5) .589 0.81 (0.378–1.737)
$6 72 (81.8) 16 (18.2)
Female (N=88) ,6 40 (85.1) 7 (14.9) *.01 3.657 (1.32–10.133)
$6 25 (61.0) 16 (39.0)
*The G1613A mutation is associated with higher serum viral load in female carriers.
#P value was determined using chi’s square analysis in SPSS software. A P-value of .05 or less is regarded as statistically significant.
##Harzard Ratio is an estimation of relative risk.
doi:10.1371/journal.pone.0021856.t003
Figure 2. The effect of G1613A mutations on the levels of HBsAg and HBeAg. (A) Intracellular level of HBsAg, (B) extracellular level of
HBsAg, (C) intracellular level of HBeAg and (D) extracellular level of HBeAg were measured after transfection with 1.36HBV genomes with indicated
mutations into HuH7 cells by ELISA as described in materials and methods. All the constructs have the same genetic backgrounds except the
indicated mutations. The mutations were introduced into the HBV genome by site directed mutagenesis. The levels of the antigens were normalized
to the transfection efficiency measured as the co-transfected SEAP activities. The decrease with statistical significance in the HBeAg in the
extracellular media is indicated by asterisk(s). Data were presented as normalized values in 4 independent experiments (mean 6 S. D.).
doi:10.1371/journal.pone.0021856.g002
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CCCTCGAGTGGCCACGTAATTCC-39) were end-radiola-
beled with
32P by T4 kinase (GE Healthcare). Unincorporated
nucleotide was removed by G-25 column (GE Healthcare)
according to manufacturer’s instruction. The DNA binding
reactions contained 5–20 mg of protein, 1 ml of labeled probe,
2 mlo f1 0 6 binding buffer (500 mM NaCl, 100 mM TrisHCl
pH 7.5, 25 mM MgCl2, 40% Glycerol, 5 mM DTT), 1 mlo f1 %
NP40 and 1 ml of poly (dI ? dC) (GE Medical Systems) in a
reaction volume of 20 ml. The reaction was incubated at room
temperature for 1 hr and then analyzed in 5% native polyacryl-
amide gel. After that, the gel was blotted to a filter paper and dried
at 75uC for 1 hr, followed by signal detection by autoradiography
or phosphorimager. To validate the specificity of the binding, up
to 2506of cold probes were added to the binding reaction before
the addition of the labeled probes. The difference in the binding
affinities was reflected by the relative intensity of the bands.
Co-transfection of pCMV-RFX1 with HBV promoters
HuH7 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS) (Hyclone) and 1% streptomycin-penicillin
(Invitrogen) at 37uC and 5% CO2. Cells were seeded on 60-mm
plate to obtain approximately 60% confluent on the day of
transfection. Then, 0.6 ml of FuGENE6 was diluted in a dropwise
manner in 20 ml of plain medium and incubated at room
temperature for 5 min. Afterwards, 0.1 mg of each of pCMV-
RFX1 plasmid and pGL3-HBV promoter plasmid and 0.001 mg
Figure 3. The effect of G1613A mutation on the HBV DNA level. The relative intracellular and extracellular HBV DNA levels were measured by
quantitative real-time PCR (A and B) and Southern blot analysis (C and D) respectively after transfection with 1.36HBV genomes into HuH7 cells.
Except the indicated mutations, all the constructs have the same genetic background. Results in real-time PCR were normalized to the wild-type and
shown in mean values 6 S.D. from 3 independent experiments. The increases of extracellular HBV DNA level with statistical significance are indicated
by asterisks. In Southern blot analysis, the amount of HBV DNA extracted from both intracellular and extracellular cores particles from each plate of
transfected cells was normalized using the SEAP activity as an internal control. The relative signals were quantified by densitometer and shown below
each graphs for comparison. GenA: Huh7 cells transfected with a replicative competent 1.56HBV plasmid (Genotype A) as positive control. ND: not
determined.
doi:10.1371/journal.pone.0021856.g003
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incubated at room temperature for 20 min. Then, 20 mlo f
mixture was added into cells and incubated at 37uCi n5 %C O 2
incubator for 2 days. Dual luciferase reporter assay was performed
according to manufacturer’s instruction.
Dual-luciferase reporter assay
Cells were harvested at 48 hr after transfection. After washing
with phosphate buffer saline (PBS), cells were lysed with 400 mlo f
16Passive Lysis Buffer (Promega) for 15 min at room temperature.
Cell lysates were centrifuged at 10,0006g for 30 s to remove cell
debris and nuclei. Luciferase assay was performed according to
manufacturer’s instruction (Promega). The results were shown as
relative ratio of the Firefly luciferase activities normalized to the
Renilla luciferase activities in triplicates (mean value 6 S.D).
Data analysis
Data was analyzed by the software SPSS version 11.5 for Windows.
Continuous variables were expressed as mean with standard deviation,
and compared by t test or Mann-Whitney U test as appropriate.
Categorical variables were compared by Chi-square test or Fisher’s
exact test as appropriate. All statistical tests were 2-sided, and P values
less than .05 will be considered as statistically significant.
Results
The higher prevalence of the G1613A mutation in HCC
patients
In our previous study, we showed the G1613A mutation is a
hotspot mutation in HBV subgenotype Cs in HCC patients [26].
Here, we further evaluate the prevalence of the mutation in HBV
genotype B and subgenotype Ce. The HBV sequences were
obtained as previously described and sequenced [30]. We showed
that the G1613A mutation was found with higher prevalence in
HCC patients in all HBV genoytpes (Table 1). Intriguingly, the
mutation is associated to HCC in subgenotype Cs (36.2%,
P,.003) with statistically significance, suggesting that the mutation
may play a role in a genotype-dependent HBV-related HCC
pathogenesis. In order to further characterize the mutation in
genotype C HBV genome, we aligned 803 HBV complete genome
sequences obtained from National Center for Biotechnology
Information (GenBank). We found the nt. 1613 is the only hotspot
in the NRE region from nt. 1604–1636. The summarized result of
alignment from nt. 1611–1619 was shown in Table 2, in which
26% of the NRE sequences contain G1613A mutation.
Association of the prevalence of G1613A mutation to
high viral load in chronic HBV carriers
Previously, a clinical scoring system for HCC risk assessment
suggested that the serum viral load more than 6 log copies/ml is
associated with higher risk in developing HCC in both univariate
and multivariate analysis [27]. To characterize the relationship
between the HBV viral load and the G1613A mutation, we
quantified the serum viral load in 255 chronic HBV carriers as
described in the previous study [12]. We also sequenced the NRE
region of HBV genomes obtained from their serum. As shown in
Table 3, 129 (41 females and 88 males) chronic carriers had their
serum viral load more than 6 log copies/ml. Moreover, the
prevalence of the G1613A mutation is significantly associated to
higher viral load in female carriers in a univariate analysis.
Although the discrepancy between sexes is unclear, the analysis
suggests that high viral load could be one of the consequences of
the G1613A mutation in HBV.
G1613A mutation drastically suppresses HBeAg secretion
and enhances viral DNA production in vitro
To demonstrate the effect of the mutations on the HBsAg and
HBeAg production, 1.36HBV genomes of subgenotype Cs with
the same genetic background but different combination of the
G1613A and BCP mutations were constructed (pG1, pA1, pG2
and pA2) and transfected into HuH7 cells. Since the BCP
mutation has high prevalence in HCC patients, it is used (pG1
and pA1) as an independent control to evaluate the effect of
G1613A mutation. The viral HBsAg and HBeAg level in the
intracellular and extracellular compartments were measured. As
shown in Figure 2, the HBsAg levels in both intracellular and
extracellular compartments, as well as the intracellular level of
HBeAg were not affected by any mutations introduced
(Figure 2A, 2B and 2C). In contrast, the G1613A mutation
significantly decreased the extracellular HBeAg level by 90%
(pA1 vs pG1) and 86% (pA2 vs pG2) (Figure 2D). Next, the core-
particle associated HBV DNA in both intracellular and extracel-
lular compartments were measured by quantitative real time PCR.
The DNA levels in A1613 mutants were normalized to that in
G1613 wild-type. As shown in Figure 3A, insignificant change is
observed in the level of intracellular HBV DNA in response to the
mutations. On the other hand, G1613A mutation significantly
increased the level of extracellular HBV DNA by 2 folds (pA1 vs
pG1) and 4 folds (pA2 vs pG2) respectively (Figure 3B). To further
confirm the enhanced viral DNA production in the mutants,
Southern blots were performed. As shown in Figure 3C and 3D, the
level of intracellular HBV DNA intermediates was not affected
whereas the level of extracellular HBV DNA significantly increased
in G1613A mutants. These results suggest that the G1613A
Figure 4. Northern blot analysis of HBV RNA. HuH7 were
transfected with 1.36HBV genomes with indicated mutations. All the
constructs have the same genetic background except the indicated
mutations. Total RNA was extracted at 5-day posttransfection.10 mgo f
total RNA were loaded in each lane. X, C and S indicate the 3.9-kb X
gene transcript, the C gene transcripts and the S gene transcripts,
respectively. The relative signals of the total core RNA (C) were
quantified by densitometer and showed below for comparison. The 18S
rRNA showed at the bottom is the internal control of RNA loading. ND:
not determined.
doi:10.1371/journal.pone.0021856.g004
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DNA synthesis.
Effect of G1613A mutation on HBV transcripts
To further investigate the functional effect of the G1613A
mutation on viral transcription, Northern blot analysis was
performed to measure the relative amount of the HBV transcripts
after the transfection of the 1.36 HBV genomes (Figure 4). The
level of HBV RNA transcription does not change significantly
when compared with HBeAg and HBV DNA levels, suggesting
that the G1613A mutation may exert its effect at the posttran-
scriptional regulation level. In fact, the G1613A mutation locates
within the conserved regions of PRE on HBV RNAs. One of the
possible reasons for the subtle change of the total core RNA level is
likely due to the combined effect of enhancement of promoter
activity and the involvement of the posttranscriptional element
(PRE) effect at the 39end of HBV transcript that affects the RNA
stability. We described in detail in the discussion section.
Figure 5. Electrophoretic mobility shift assay of wild-type and G1613A NRE oligos. (A) Binding of HuH7 nuclear and cytosolic fractions to
the wild-type and mutant NRE oligos. The radioactive labeled oligos were titrated with 5 mg nuclear extracts and the complexes were analyzed by
native polyacrylamide gel electrophoresis (PAGE). The cytosolic extracts and non-specific probes were used as negative controls. The complexes are
shown as C1 and C2. The non-specific complex is indicated with an asterisk. (B) Titration of the WT and Mut oligos against increasing amount of
nuclear extracts. Various amounts of nuclear extracts were used to bind the WT and Mut oligos and analyzed by native PAGE. (C) The competitive
binding of protein complexes against unlabeled wild-type and mutant NRE oligos. The complexes were titrated against various amounts of unlabeled
oligos (106,5 0 6and 2506) and the displacement of the labeled oligos from the complexes was analyzed by native PAGE. NE: Nuclear Extract; Cyto:
cytosolic fraction; WT: Wild-type oligos; Mut: Mutant oligos; NS: Non-specific oligos; C1: Protein complex I; C2: Protein complex II; *: non-specific
complex.
doi:10.1371/journal.pone.0021856.g005
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NRE
To gain insight into the molecular effect of the G1613A
mutation, NRE DNA binding with nuclear proteins was studied
using EMSA. As shown in Figure 5A, two specific DNA-protein
complexes (C1 and C2) were observed when the NRE oligos were
incubated with nuclear but not cytosolic extracts, suggesting that
the promoter interacts with the nuclear proteins in the cells.
Moreover, the DNA binding to the nuclear proteins showed a
dosage-dependent manner (Figure 5A and 5B). Intriguingly, the
formation of C1 complexes is more favorable to wild-type than
mutant whereas that of C2 complexes is more favorable to mutant.
In order to further study their affinity and specificity, we titrated
the complexes against increasing concentration of non-radioactive
DNA. As shown in Figure 5C, DNA of C1 complex was displaced
by 506(wild-type) and 2506(mutant) non-radioactive oligos. On
the other hand, DNA of C2 complex was displaced readily by 106
non-radioactive mutant DNA. Our results implied that two
different binding mechanisms are involved in NRE in the context
of G1613A mutation, and the mutation can modify the binding of
two nuclear protein complexes to NRE region.
RFX1 protein binds on the NRE and transactivates the
core promoter activity corresponds to the G1613A
mutation
The NRE contains three subregions which act synergistically to
suppress core promoter activity. NREc (nt. 1605–1625) is one of
these subregions that is active in HuH7 cells [14]. RFX1 is one of
the transcription activator that was shown to bind NREc on the
core promoter [14,31]. Moreover, the consensus binding sequenc-
es of RFX1 share extremely high homology with the sequence of
NREc subregion, from nt. 1605 to 1617 [26,32,33,34] (Figure 6A).
Intriguingly, the G1613A mutation on the NREc site further
matches the consensus RFX1 binding sequence, which is
consistent to our result that the C2 complex showed higher
affinity to mutant than wild-type DNA. In order to further confirm
this result, we in vitro synthesized the RFX1 protein using rabbit
reticulocyte lysate which showed a 130 kDa on SDS-PAGE
(Figure 6B). Then we performed EMSA using the in vitro
synthesized protein and NRE probes. As shown in Figure 6C,
RFX1 shifted the wild-type and mutant NRE probe to the position
correspond to that in the complex C2, suggesting that the C2
complex is possibly the RFX1-DNA complex. This only occurred
in the NRE probes but not in the NS oligos and control, indicating
the specificity between RFX1 and the DNA. Moreover, the
G1613A mutation can alter the binding of RFX1 binding to NRE,
in which that the RFX1 protein favors for the A1613 mutant then
the wild-type. This implied that the RFX1 could possibly be one of
the protein complexes which binding to NRE can be modulated
by G1613A mutation.
To further investigate the role of the RFX1 on HBV core
promoter via G1613A mutation, C-terminally myc-tagged RFX1
protein was overexpressed in HuH7 cells. As shown in Figure 7A,
under the physiological level of RFX1, the mutated core promoter
was more active when compared to wild-type. However, when
RFX1 was overexpressed, it enhanced the activity of the wild-type
promoter to the level of mutant, and further enhanced the mutant
promoter activity. Notify that the protein had no effect on the
PreS1 promoter and empty-vector control, indicating the
transactivation effect was specific to core promoter. The
overexpression of the RFX1 was confirmed by immunoblotting
using mouse anti-myc antibody (Figure 7B). These results suggest
that RFX1 plays a significant role on regulating HBV core
promoter via G1613A mutation on NRE.
Discussion
Infection of hepatitis B virus (HBV) causes acute and chronic
hepatitis and is closely associated with the development of cirrhosis
Figure 6. Binding of recombinant RFX1 to wild-type and
G1613A mutant NRE. (A) Sequence alignment of the consensus
binding sequence of RFX1 and the NREc region. The consensus
sequence of RFX1 was aligned with the sequence of the NREc region
(nt. 1605–1617). The underlined ‘G’ corresponds to the nt.1613 position
in our study. (B) In vitro expression of RFX1 using radioactive
35S
methionine. 1–5 mg of RFX1-expression construct was used for each
reaction. The in vitro synthesized RFX1 protein was revealed using 10%
SDS-PAGE and the signals were detected by autoradiography for 2 days.
RFX1 of apparent size of 130 kDa was successfully expressed. The smear
observed may be due to the degradation of proteins of large size. No
band was shown in the empty vector control. The 62 kDa protein in the
control correspond to the luciferase protein expressed from a control
plasmid provided by the kit. (C) Electrophoretic mobility shift assay of
Wt and Mut radioactive labeled oligos with recombinant RFX1 protein.
The complexes were analyzed by native polyacrylamide gel electro-
phoresis. Non-specific oligos and in vitro transcribed luciferase protein
were used as negative control. The labeling is depicted as previously
described.
doi:10.1371/journal.pone.0021856.g006
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patients with chronic HBV infection, prognosis of the risk of
cancer development will be essential because of the lack of
effective drug treatments. Previously, we showed that the G1613A
mutation in the HBV core promoter is a hotspot in HCC patients,
which could be a potential biomarker for risk evaluation of HCC.
G1613A mutation was found in HCC patients [35], particularly
associates to subgenotype Cs as we demonstrated in this study.
Persistent elevation of serum HBV DNA level in the 10
4–10
7
ranges has long considered increasing the risk of HCC [30].
Moreover, a recent report showed that high HBV viral load (more
than 6 log copies/ml) is significantly associated with HCC in both
univariate and multivariate analysis [17,23,36,37,38,39,40,41]. In
this report, we showed that the G1613A mutation is associated to a
viral load of more than 6 log copies/ml in female carriers,
indicating that there may be a link between this mutation and the
HBV-related HCC development through the enhanced viral load.
However, the reason for the discrepancy between sexes is
still not clear. Moreover, we further investigated the functional
consequences of the G1613A mutation in the context of 1.36full-
length replicative competent HBV genomes and provide a possible
molecular mechanism of the G1613A mutation and resulted
phenotype of the virus.
Our work demonstrated that the G1613A mutation leads to
the suppression of HBeAg secretion. Downregulation of HBeAg
results in the moderation of HBcAg-specific liver injury and viral
persistency during chronic infection, leading to severe liver disease
in various studies [23,41,42,43,44]. Emergence of HBeAg
negative/reduced mutant during chronic infection can also lead
to more active disease on liver histology, especially when the
mutant becomes predominant with high viral load in serum [45].
In our results, the phenotype of the G1613A mutation which
includes the suppression of HBeAg secretion and the enhancement
of viral DNA production may indicate a more aggressive disease
stage of liver introduced by this mutation.
Our result also demonstrated that there was no correlation
between the level of HBsAg and the G1613A mutation. HBsAg
has been a surrogate marker for covalently closed circular (ccc)
Figure 7. The effect of RFX1 on the HBV promoter activity. (A) The relative luciferase activities of the HBV promoters were measured after the
overexpression of RFX1 (48 hr) in HuH7 cells. The pCMV, PreS1 promoters and pGL3-basic were used as negative controls. Results were presented as
relative luciferase activity in 3 independent experiments with triplicates (mean 6 S. D.) after normalizing to the co-transfected Renilla luciferase
activities. CP: HBV Core promoter; PreS1: HBV PreS1 promoter. (B) Western blot of the RFX1 protein. The RFX1 protein (130 kDa) was probed with
anti-myc antibody after 48 hours of transfection. b-actin (42 kDa) was the internal control.
doi:10.1371/journal.pone.0021856.g007
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that responsible for the viral persistence [46,47,48]. However,
most studies investigating the association between serum HBsAg
and cccDNA have focused mainly on patients with a positive
HBeAg [49]. Recently, it has been reported that HBsAg cannot
reflect the replication efficiency of HBV in patients with HBeAg-
negative chronic hepatitis B [12,13,50,51,52]. This may be
explained by the massive production of HBsAg from the cells as
subviral quasispheral or filamentous lipoprotein particles without
the component of core capsid and viral DNA, in addition to being
incorporated into virion envelope.
A number of studies showed that mutations in NRE destroyed
most of its activity and increased the core promoter activity [53].
However, the functional consequences of G1613A mutation are
not yet to be determined. We demonstrated for the first time that
the nt. 1613 is the hotspot of mutation within the NRE region.
Moreover, we found two main protein complexes that associated
with NRE sequence of core promoter and showed differential
binding affinity towards the wild-type and mutant NRE sequences,
suggesting the possible role of the G1613A mutation on regulating
core promoter activity, and hence modulating viral replication and
protein secretion. We further identified a transactivator of the
HBV enhancer I, RFX1 [54], binds to the G1613A mutant with
higher affinity than the wild-type sequence and possesses the trans-
activating effect to enhance the core promoter activity in liver cells.
Intriguingly, the G1613A mutated NRE sequence share higher
homology with the consensus RFX1 binding sequence than the
wild-type sequence, indicating the higher affinity of the mutant
NRE to the protein leads to the transactivation of the core
promoter activity.
As the mutation alters the core promoter activity, however, the
levels of HBV transcripts were not significantly affected. All HBV
mRNAs have a common polyadenylation site and the highly
conserved regions of PRE at the 39 end. Intriguingly, the minimal
region of the PRE was shown within nt. 1151–1684 [20] in which
our G1613A mutation is found. The PRE has been reported to be
involved in the regulation of HBV mRNAs including RNA
splicing [19], RNA stability [15,16,54] and nuclear export [18].
Computational analysis of the PRE sequence revealed three
putative functional conserved elements whereas one of them (nt.
1510–1620) contains a conserved and defined RNA secondary
structure [55]. The G1613A mutation within this region may
possibly disrupts this secondary structure and hence, affect the
function of PRE. Indeed, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) [37] and polypyrimidine tract binding protein
(PTB) [38] have been shown to bind to the full length PRE (nt.
1239–1805) except the region nt. 1375–1487 [20]. The functional
role of these proteins binding to PRE was believed to increase
HBV gene expression at the posttranscriptional level, probably by
increasing viral RNA export out of the nucleus. Moreover, PTB is
known to contribute to RNA stability [39] and translation
initiation [37,56]. It also represses pgRNA splicing and facilitates
the export of unspliced subgenomic RNAs. Whether the G1613A
mutation affect the binding to these proteins deserves to be
investigated in the future. Interestingly, although all HBV RNAs
contain the same PRE sequence, it seems that the function of the
PRE is differentially regulated depending on the context of the
RNA sequences [15,54,57]. For example, the PRE is considered to
enhance HBV surface protein expression by facilitating nuclear
export of subgenomic RNAs [20]. In contrast, the PRE has been
shown to contributed to pgRNA splicing and stability [58].
However, its role in the metabolism of the pgRNA is not well
understood. Nevertheless, in our study, the G1613A mutation
affects not only at promoter level but also possibly posttranscrip-
tionally, suggesting the tightly regulated processes of HBV
replication.
In summary, we demonstrated that the G1613A mutation, a
hotspot mutation on NRE found in HCC patients suppresses the
HBeAg secretion and enhances the viral load, which may possibly
lead to a more active hepatitis and the risk to HCC. Moreover, we
demonstrated that RFX1 plays a significant role on transactivating
HBV core promoter activity with the G1613A mutation and
suggested a possible molecular linkage between this mutation and
the resulted phenotype of the virus.
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